In randomized controlled trials, there are two treatment selections currently viewed as the conventional of care in Guillain-Barré syndrome (GBS). These contain both intravenous immunoglobulin (IVIG) or plasma Trade. IVIG is believed to act by its immune-modulating action; on the other hand, the exact mechanism continues to be to be elucidated. I